LexaGene Announces Advancements to its Sample Preparation Cartridge for the Veterinary Market BEVERLY, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System, a...

LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing BEVERLY, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...

LexaGene’s MiQLab Detects Common Bioreactor Contaminant up to 300 Times Faster than Conventional Methods Mycoplasmas are thought to contaminate 15-80% of cell cultures worldwideMiQLab rapidly detected 100% of the tested mycoplasma samples within two hours, with no false positivesMiQLab can be used inside...

LexaGene Retains Wolf Greenfield Intellectual Property Law Firm BEVERLY, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a molecular diagnostics company that develops a fully automated rapid pathogen...